Sequence-dependent growth inhibition and DNA damage formation by the irinotecan-5-fluorouracil combination in human colon carcinoma cell lines

European Journal of Cancer

Volumn 35, Issue 13, 1999, Pages 1851-1861

  Mans, D R A ^a   Grivicich, I ^b   Peters, G J ^a   Schwartsmann, G ^c  

^a South American Office for Anticancer Drug Development (SOAD)   (Netherlands)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

5 fluorouracil (5 FU); Carboxyl esterase; Cell growth inhibition; Colon carcinoma cell lines; Combinations; DNA damage; Drug interactions; Irinotecan (CPT 11); Thymidylate synthase; Topoisomerase I

Indexed keywords

CARBOXYLESTERASE; DNA; DNA TOPOISOMERASE; FLUOROURACIL; IRINOTECAN; LIGAND; RHODAMINE B; THYMIDYLATE SYNTHASE;

ARTICLE; CARCINOMA CELL; COLON CARCINOMA; CONTROLLED STUDY; DNA DAMAGE; ENZYME ACTIVITY; FLUORESCENCE; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SPECTROPHOTOMETRY;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CELL DIVISION; COLONIC NEOPLASMS; DNA DAMAGE; DNA, NEOPLASM; FLUOROURACIL; HUMANS; TUMOR CELLS, CULTURED;

EID: 0032738164     PISSN: 09598049     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0959-8049(99)00222-1     Document Type: Article

References (51)

1. Jessup JM, McGinnis LS, Winchester DP, et al. Clinical highlights from the national cancer data base: 1996. CA Cancer J Clin 1996,46, 185-187.
2. Cohen AM, Minsky BB, Schilsky RL. Cancer of the colon. In DeVita VT, Hellman S, Rosenberg AS, eds. Cancer: Principles and Practice of Oncology. Philadelphia, U.S.A, Lippincott-Raven, 1997, 1144-1196.
3. Pinedo HM, Peters GJ. Fluorouracil: biochemistry and pharmacology. J Clin Oncol 1988, 10, 1653-1664.
4. Peters GJ, Van Groeningen CJ. Clinical relevance of biochemical modulation of 5-fluorouracil. Ann Oncol 1991, 2, 469-480.
5. Advanced Colorectal Cancer Meta-analysis Project. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J Clin Oncol 1992, 10,896-903.
6. Santi DV, McHenry CS, Sommer H. Mechanism of interaction of thymidylate synthase with 5-fluorodeoxyuridylate. Biochemistry 1974, 13,471-481.
7. Peters GJ, Köhne CH. Fluoropyrimidines as antifolate drugs. In Jackman AL, éd. Anticancer Drug Development Guide: Anfifolate Drugs in Cancer Therapy. Totowa, U.S.A, Humana Press, 1997, 101-145.
8. Jackman AL, Farrugia DC, Gibson W, et al. ZD1694 (Tomudex): a new thymidylate synthase inhibitor with activity in colorectal cancer. EurJ Cancer 1995, 31A, 1277-1282.
9. Machover D, Diaz-Rubio E, De Gramont A, et al. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines. Ann Oncol 1996, 7, 95-98.
10. Takimoto CH, Arbuck SG. Camptothecins. In Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, U.S.A, Lippincott Raven, 1996, 463484.
11. Jansen WJ, Zwart B, Hulscher ST, et al. CPT-11 in human colon cancer cell lines and xenografts: characterization of cellular sensitivity determinants. Int J Cancer 1997, 70, 335-340.
12. Shimada Y, Yoshino M, Wakui A, et al. CPT-11 Gastrointestinal Study Group. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. J Clin Oncol 1993, 11, 909-913.
13. Tanizawa A, Fujimori A, Fujimori Y, et al. Comparison of topoisomerase I inhibition, DNA damage, and cytotoxicity of camptothecin derivatives presently in clinical trials. J Natl Cancer Inst 1994, 86, 836-842.
14. Shimada Y, Rougier P, Pitot H. Efficacy of CPT-11 (irinotecan) as a single agent in metastatic colorectal cancer. Eur J Cancer 1996, 32A(Suppl. 3), S13-S17.
15. Pito HC, Wender DB, O'Connell MJ, et al. Phase II trial of irinotecan in patients with metastatic colorectal carcinoma. J Clin Oncol 1997, 15, 2910-2919.
16. Rougier P, Bugat R, Douillard JY, et al. Phase II study of irinotecan in the treatment of advanced colorectal cancer in chemotherapy-naive patients and patients pretreated with fluorouracilbased chemotherapy. J Clin Oncol 1997, 15, 251-260.
17. Sasaki Y, Ohtsu A, Shimada Y, et al. Simultaneous administration of CPT-11 and fluorouracil: alteration of the pharmacokinetics of CPT-11 and SN-38 in patients with advanced colorectal cancer. J Natl Cancer Inst 1994, 86, 1096-1098.
18. Saltz LB, Kanowitz J, Kemeny NE, et al. Phase I clinical and pharmacokinetic study of irinotecan, fluorouracil, and leucovorin in patients with advanced solid tumours. J Clin Oncol 1996. 14,2959-2967.
19. Saltz L, Shimada Y, Khayat D. CPT-11 (irinotecan) and 5fluorouracil: a promising combination for therapy of colorectal cancer. Eur J Cancer 1996, 32A(Suppl. 3), S24-S31.
20. Ducreux M, Rougier Ph, Ychou M, et al. Phase I/II study of escalating dose of CPT-11 in combination with LV5FU2 ('De Gramont regimen') every two weeks in the treatment of colorectal cancer (CRC) after 5-FU failure. Proc Am Soc Clin Oncol 1997. 16, 234a.
21. Goldberg RM, Erlichman C. Irinotecan plus 5-FU and leucovorin in advanced colorectal cancer: North American trials. Oncology (Huntingt) 1998, 12(Suppl. 6), 59-63.
22. Khayat D, Gil-Delgado M, Antoine EC, et al. European experience with irinotecan plus fluorouracil/folinic acid or mitomycin. Oncology (Huntingt) 1998, 12(Suppl. 6), 64-67.
23. Van Cutsem E, Pozzo C, Starkhammer H, et al. A phase II study of irinotecan alternated with five days bolus of 5-fluorouracil and leucovorin in first-line chemotherapy of metastatic colorectal cancer. Ann Oncol 1998, 9, 1199-1204.
24. Vanhoefer U, Harstrick A, Köhne C-H, et al. Phase I study of a weekly schedule of irinotecan, high-dose leucovorin, and infusional fluorouracil as first-line chemotherapy in patients with advanced colorectal cancer. J Clin Oncol 1999, 17, 907-913.
25. Guichard S, Hennebelle I, Bugat R, et al. Cellular interactions of 5-fluorouracil and the camptothecin analogue CPT-11 (irinotecan) in a human colorectal carcinoma cell line. Biochem Pharmacol 1998, 55, 667-676.
26. Schleucher N, Harstrick A, Stahl M, et al. Evaluation of the interactions of SN-38, a topoisomerase I inhibitor, and various cytotoxic agents in established human colorectal and lung carcinoma lines. Proc Am Assoc Cancer Res 1996, 37, 288.
27. Kano Y, Suzuki K, Akutsu M, et al. Effects of CPT-11 in combination with other anticancer agents in culture. Int J Cancer 1992, 50, 604-610.
28. Matsuoka R, Yano K, Takiguchi S, et al. Advantage of combined treatment of CPT-11 and 5-fluorouracil. Anticancer Res 1995, 15, 1447-1452.
29. Pavillard V, Formento P, Rostagno P, et al. Combination of irinotecan (CPT-11) and 5-fluorouracil with an analysis of cellular determinants of drug activity. Biochem Pharmacol 1998, 56, 1315-1322.
30. Funakoshi S, Aiba K, Shibata H, et al. Enhanced antitumour activity of SN-38, an active metabolise of CPT-11, and 5-fluorouracil combination for human colorectal cancer cell lines. Proc Am Soc Clin Oncol 1993, 12, 193.
31. Van Triest B, Pinedo HM, Van Hensbergen Y, et al. Thymidylate synthase level as the main predictive parameter for sensitivity to 5-fluorouracil, but not for folate-based thymidylate synthase inhibitors, in 13 non-selected colon cancer cell lines. Clin Cancer Res 1999, 5, 643-654.
32. Monks A, Scudiero D, Skehan P, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumour cell lines. J Natl Cancer Inst 1991, 83, 757-766.
33. Chou T-C, Talahay P. Quantitative analysis of dose-effect relationship: the combined effects of multiple drugs on enzyme inhibitors. In Weber G, ed. Advances in Enzyme Regulation. New York, U.S.A, Pergamon Press, 1983, 27-55.
34. Van der Wilt CL, Pinedo HM, Smid K, et al. Elevation of thymidylate synthase following 5-fluorouracil treatment is prevented by the addition of leucovorin in murine colon tumours. Cancer Res 1992, 52, 4922-4928.
35. Peters GJ, Van Groeningen G, Laurensse E, et al. Thymidylate synthase from untreated human colorectal cancer and colonie mucosa: enzyme activity and inhibition by 5-fluoro-2'-deoxyuridine-5'-monophosphate. Eur J Cancer 1991, 27A, 263-267.
36. Lowry OH, Rosebrough NJ, Farr L, et al. Protein measurement with the folin phenol reagent. J Biol Chem 1951, 193, 265-275.
37. De Jong S, Zijlstra JG, de Vries EGE, et al. Reduced DNA topoisomerase II activity and drug-induced DNA cleavage activity in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res 1990, 50, 304-309.
38. Heymann E, Mentlein R. Carboxylesterases - amidases. Meth Enzymol 1981, 77, 333-344.
39. Kanter PM, Schwartz HS. A fluorescence enhancement assay for cellular DNA damage. Mol Pharmacol 1982, 22, 145-151.
40. Bergman AM, Ruiz van Haperen VWT, Veerman G, et al. Synergisitic interaction between cisplatin and gemcitabine in vitro. Clin Cancer Res 1996, 2, 521-530.
41. Grem JL. Fluoropyrimidines. In Chabner BA, Longo DL, eds. Cancer Chemotherapy and Biotherapy: Principles and Practice. Philadelphia, U.S.A, Lippincott-Raven, 1996, 149-212.
42. Van der Wilt CL, Smid K, Aherne GW, et al. Biochemical mechanisms of interferon modulation of 5-fluorouracil activity in colon cancer cells. Eur J Cancer 1997, 33, 471-478.
43. Peters GJ, Laurensse E, Leyva A, et al. Sensitivity of human, murine, and rat cells to 5-fluorouracil and 5'-deoxy-5-fluorouridine in relation to drug-metabolizing enzymes. Cancer Res 1986,46, 20-28.
44. Major PP, Egan E, Herrick D, et al. 5-Fluorouracil incorporation in DNA of human breast carcinoma cells. Cancer Res 1982, 12, 3005-3009.
45. Schuetz JD, Wallace HJ, Diasio RB. 5-Fluorouracil incorporation into DNA of CF-1 mouse bone marrow cells as a possible mechanism of toxicity. Cancer Res 1984, 44, 1358-1363.
46. Porquier P, Ueng LM, Kohlhagen G, et al. Effects of uracil in incorporation, DNA mismatches, and abasic sites on cleavage and religation activities of mammalian topoisomerase I. J Biol Chem 1997, 272, 7792-7796.
47. Mattern MR, Zwelling LA, Kerrigan DJ, et al. Reconstitution of higher order DNA structure following X-irradiation. Biochem Biophys Res Commun 1993, 112, 1077-1084.
48. Mattern MR, Hofmann GA, McCabe FL, et al. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Res 1991, 51, 5813-5816.
49. Naoko M, Nakano S, Esaki T, et al. Modulation of the removal of cisplatin-induced interstrand cross-links by 7-ethyl-10hydroxy-camptothecin (SN-38) in a human squamous carcinoma cell line. Proc Am Assoc Cancer Res 1994, 35, A1984.
50. Mans DRA, Lafleur MVM, Westmijze EJ, et al. Formation of different reaction products with single- and double-stranded DNA by the ortho-quinone and the semi-quinine free radical of etoposide (VP-16-213). Biochem Pharmacol 1991, 42, 2131 -2139.
51. Goldwasser F, Shimizu T, Jackman J, et al. Correlations between S and G2 arrest and the cytotoxicity of camptothecin in human colon carcinoma cells. Cancer Res 1996, 56, 4430-4437.